Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAt 0.25mg, Wegovy is not expected to produce significant weight loss. The starter dose exists for one reason: to help your body adjust to semaglutide before stepping up to doses where the real work begins. Clinical trials that measured meaningful weight reduction used higher maintenance doses — on average around 15% body weight over 68 weeks at 2.4mg, according to the STEP 1 trial published in the New England Journal of Medicine. Like all doses of Wegovy, the 0.25mg starting pen is a prescription-only medicine: a clinician assesses whether it is suitable for you before it is prescribed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is a common and completely understandable assumption: you start Wegovy, the dose says 0.25mg on the pen, and you expect the scales to shift. Many people arrive at this question having read headline trial figures and wondered why their first few weeks feel unremarkable. The truth is that 0.25mg is a tolerability step, not a therapeutic target. Novo Nordisk designed the escalation schedule (starting at 0.25mg and moving through 0.5mg, 1.0mg, 1.7mg, and 2.4mg over roughly four months) specifically to give the body time to settle before reaching the doses where appetite suppression becomes clinically meaningful.
At 0.25mg, semaglutide is in your system, and some people do notice mild changes in appetite or digestion early on, and if you are curious about how much weight you can lose on 0.25 Wegovy at this early stage, the honest answer is that the starter dose is not where the clinical results were built. The prescriber-titrated schedule exists precisely because the full effect on weight takes time to build. NICE's appraisal of semaglutide (TA875) assessed the medicine at its maintenance dose of 2.4mg, not the starter step. Expecting the 0.25mg pen to deliver the same results as the 2.4mg maintenance dose is a bit like judging a car's top speed at first gear. Let it go gently: the starter dose is doing its job, even when the scales stay quiet.
If you want a fuller picture of what outcomes look like across the full titration, our overview of how much weight Wegovy can help you lose covers the clinical evidence at each stage.
UK private weight-loss treatment is priced per pen or per month and varies between providers. Since Eli Lilly's list price revision in September 2025 (which pushed the highest-dose Mounjaro pen from roughly £122 to around £330), the broader market for GLP-1 medicines has seen prices recalibrated across providers. For Wegovy, if you want to understand what shapes the Wegovy weight loss price you see quoted, it helps to know that figures typically reflect dose, provider, and what the price actually bundles, as widely reported through 2025 and into 2026.
What matters is what sits behind the headline number. Some providers quote a per-pen figure that does not include the initial consultation, the prescription fee, delivery, or any clinical follow-up between orders. You find out at the checkout, or at your first dose increase, that the advertised figure was the floor. Our Wegovy pricing page sets out exactly what is included at nume so there are no surprises.
For a Wegovy treatment course priced correctly, you should expect the quoted amount to cover the clinical assessment, a GPhC-registered prescriber reviewing your case, the prescription, the medicine, and delivery. Aftercare (the support available if you have questions between pens) is worth asking about specifically, because it is often where cheaper services cut corners.
We are not the cheapest option for Wegovy. That is deliberate. A small saving on a prescription medicine is the wrong trade-off if it comes at the cost of proper clinical oversight, verified supply, or aftercare when you need it. For a GLP-1 receptor agonist prescribed under UK law (where the medicine is prescription-only and must be assessed by a qualified prescriber) the relevant question is not which provider charges least, but which one can demonstrate it is operating safely and legitimately.
At nume, one price covers everything: your free consultation, a same-day clinical review by a named GPhC-registered prescriber, your prescription, the treatment, and free next-working-day DPD delivery in plain packaging. No add-ons, no subscription, no auto-renewal. Our pharmacy's GPhC registration (number 9012878) can be verified directly at the GPhC online register. Every repeat order is reviewed again before dispatch, because your clinical picture can change, and a prescriber should know about it. Details about our clinical team are on our prescriber profile page.
If you have seen discount codes or unusually low prices for Wegovy online, treat them as a red flag. The MHRA has warned publicly about fake weight-loss pens sold without any clinical assessment, some containing incorrect or dangerous substances. Reporting suspicious sellers through the Yellow Card scheme helps protect others. Legitimate supply of Wegovy in the UK flows through a licensed supply chain, requires a valid prescription, and comes from a pharmacy you can verify.
Meaningful weight reduction on Wegovy typically becomes noticeable once the dose reaches 1.0mg and above, though individual responses vary. The 68-week STEP 1 trial that informed NICE's recommendation reported an average of around 15% body-weight reduction at the 2.4mg maintenance dose, a figure that took the full titration period and beyond to accumulate. Weight loss on GLP-1 medicines is gradual and individual; the first weeks are not where the evidence was built.
What you can usefully think about at the 0.25mg stage is how well you are tolerating the medicine, whether you are eating alongside a reduced-calorie diet as recommended, and whether you have any questions for your prescriber before moving up. Our FAQs page covers common questions about what to expect at each stage, and our clinical team is available seven days a week for aftercare queries. If you want a clearer sense of how much weight you will lose on 0.25 Wegovy before your dose increases, that page works through the realistic expectations at this early point in the titration. For those also weighing up the cost of higher doses, our page on Wegovy 7.5mg price explains what the later stages of treatment typically cost. If you are exploring what the full treatment journey looks like before committing, our treatment overview is a good place to start.
Semaglutide is licensed for weight management only when prescribed following clinical assessment. A prescriber decides suitability; the titration schedule is theirs to guide. If you are ready to find out whether Wegovy is right for you, the first step is a free consultation, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.